Biogen Inc. (BIIB) is the 8th largest of 300 Biotechnology companies by market capitalisation, at 32.63 Bn, behind Alnylam Pharmaceuticals, Inc. at 35.59 Bn. It trades on a P/E of 39.08, 117% above the peer median of 17.97. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 236.37 Bn | 27.00 | 6.20 | 222.38 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.38 Bn | -64.83 | 6.15 | 184.12 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 138.36 Bn | 31.45 | 10.99 | 130.51 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 85.09 Bn | 19.66 | 5.48 | 77.10 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.93 Bn | 36.92 | 12.23 | 58.75 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 58.07 Bn | -18.38 | 26.07 | 52.94 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.59 Bn | 45.89 | 7.41 | 32.28 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.63 Bn | 39.08 | 3.25 | 31.34 Bn |
| 9 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.57 Bn | -31.36 | 24.23 | 26.41 Bn |
| 10 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 26.24 Bn | -14.72 | 8.48 | 12.58 Bn |
| 11 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.24 Bn | -16.96 | 2,310.98 | 25.93 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.77 Bn | 18.91 | 11.83 | 15.82 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.77 Bn | -49.43 | 12.28 | 14.93 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.62 Bn | -21.18 | 20.50 | 13.91 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.96 Bn | — | — | 13.27 Bn |
| 16 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.88 Bn | 176.35 | 3.78 | 12.00 Bn |
| 17 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.57 Bn | 31.25 | 7.55 | 12.34 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.19 Bn | -45.49 | 18.20 | 10.58 Bn |
| 19 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.15 Bn | 74.93 | 14.45 | 11.63 Bn |
| 20 | AAVXF | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 21 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 22 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.82 Bn | -26.87 | — | 9.06 Bn |
| 23 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.62 Bn | -45.28 | 11.01 | 7.57 Bn |
| 24 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.42 Bn | 87.02 | 33.42 | 9.42 Bn |
| 25 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.86 Bn | -8.36 | — | 8.86 Bn |
| 26 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.57 Bn | 17.97 | 10.72 | 7.89 Bn |
| 27 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.51 Bn | -8.55 | 51.33 | 8.15 Bn |
| 28 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.10 Bn | -14.99 | — | 8.10 Bn |
| 29 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.84 Bn | -42.14 | — | 7.84 Bn |
| 30 | GIFLF | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 31 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.07 Bn | -33.52 | 29.47 | 6.74 Bn |
| 32 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.97 Bn | -734.96 | 5,007.81 | 6.97 Bn |
| 33 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.73 Bn | -17.90 | — | 6.73 Bn |
| 34 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.59 Bn | -29.38 | 1,058.74 | 6.59 Bn |
| 35 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.53 Bn | -7.43 | 10.57 | 6.10 Bn |
| 36 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.96 Bn | -16.08 | — | 5.96 Bn |
| 37 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.84 Bn | -33.18 | 1,163.52 | 5.66 Bn |
| 38 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.82 Bn | — | — | 4.09 Bn |
| 39 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.78 Bn | -16.41 | — | 5.78 Bn |
| 40 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.77 Bn | 15.04 | 5.72 | 3.55 Bn |
| 41 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.69 Bn | 29.05 | 19.58 | 4.33 Bn |
| 42 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.06 Bn | -17.55 | — | 5.06 Bn |
| 43 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.68 Bn | -23.96 | — | 4.68 Bn |
| 44 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.63 Bn | — | — | 4.23 Bn |
| 45 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.16 Bn | -13.51 | 402.01 | 4.16 Bn |
| 46 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.07 Bn | -7.58 | — | 4.07 Bn |
| 47 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.02 Bn | -7.78 | — | 4.02 Bn |
| 48 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.84 Bn | -16.67 | 16.41 | 3.01 Bn |
| 49 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.80 Bn | -31.20 | — | 3.80 Bn |
| 50 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.79 Bn | -32.98 | 70.47 | 2.78 Bn |
| 51 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.77 Bn | -8.13 | 32.18 | 3.06 Bn |
| 52 | TLPPF | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.72 Bn | -521.64 | 4.64 | 3.43 Bn |
| 53 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.56 Bn | -8.16 | 987.61 | 3.56 Bn |
| 54 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.50 Bn | -21.21 | 52.94 | 3.50 Bn |
| 55 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | -10.05 | 19,714.47 | 3.11 Bn |
| 56 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.04 Bn | -15.22 | — | 3.04 Bn |
| 57 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.03 Bn | -11.21 | 593.06 | 2.51 Bn |
| 58 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.00 Bn | 109.49 | 6.47 | 2.76 Bn |
| 59 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.96 Bn | -28.23 | — | 2.96 Bn |
| 60 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | -15.57 | 6.55 | 2.24 Bn |
| 61 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.80 Bn | -80.78 | — | 2.80 Bn |
| 62 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.73 Bn | -22.89 | 553.22 | 2.73 Bn |
| 63 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.71 Bn | -8.51 | 73.73 | 2.27 Bn |
| 64 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.60 Bn | -6.02 | 36.49 | 2.60 Bn |
| 65 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.59 Bn | -6.44 | — | 2.59 Bn |
| 66 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | -6.59 | 4.75 | 2.19 Bn |
| 67 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.45 Bn | -20.64 | 44.92 | 1.77 Bn |
| 68 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | -2,975.41 | — | 2.38 Bn |
| 69 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.37 Bn | -4.03 | — | 2.10 Bn |
| 70 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.34 Bn | -7.91 | 44.88 | 2.34 Bn |
| 71 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.30 Bn | -10.51 | — | 1.93 Bn |
| 72 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.22 Bn | -9.16 | — | 2.22 Bn |
| 73 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | -15.84 | 109.75 | 2.19 Bn |
| 74 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 13.20 | 4.23 | 2.03 Bn |
| 75 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | 0.17 | 0.34 | 0.66 Bn |
| 76 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -35.67 | 11.42 | 2.05 Bn |
| 77 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | -14.21 | 56.15 | 1.81 Bn |
| 78 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | -4.99 | 2,082.32 | 2.08 Bn |
| 79 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | -12.36 | 18.84 | 1.60 Bn |
| 80 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | -4.78 | 20.06 | 1.97 Bn |
| 81 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.94 Bn | -3.72 | 35.35 | 1.39 Bn |
| 82 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | -7.59 | 6.35 | 1.93 Bn |
| 83 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -9.47 | 67.43 | 1.57 Bn |
| 84 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -101.76 | 4.32 | 0.98 Bn |
| 85 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -6.99 | — | 1.32 Bn |
| 86 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.83 Bn | -10.09 | 7.27 | 1.29 Bn |
| 87 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.80 Bn | -4.55 | — | 1.80 Bn |
| 88 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | -14.23 | 1,370.98 | 1.78 Bn |
| 89 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.75 Bn | -27.67 | — | 1.39 Bn |
| 90 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.74 Bn | -207.39 | 1,008.79 | 1.73 Bn |
| 91 | GLPGF | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 92 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.71 Bn | -12.73 | — | 1.71 Bn |
| 93 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -6.79 | 4.07 | 0.97 Bn |
| 94 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -118.55 | 16.97 | 1.68 Bn |
| 95 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -9.11 | 20.12 | 1.38 Bn |
| 96 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.65 Bn | -68.24 | 8.28 | 1.36 Bn |
| 97 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 98 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | -8.49 | — | 1.53 Bn |
| 99 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | -11.47 | 969.66 | 1.31 Bn |
| 100 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | -3.37 | 2.10 | 1.22 Bn |
| 101 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -9.00 | — | 1.50 Bn |
| 102 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -14.58 | 72.74 | 1.45 Bn |
| 103 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -6.70 | — | 1.42 Bn |
| 104 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -5.85 | 165.97 | 0.88 Bn |
| 105 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | 80.09 | 35.55 | 1.37 Bn |
| 106 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | -1.48 | — | 1.36 Bn |
| 107 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | -8.83 | — | 1.33 Bn |
| 108 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -4.18 | — | 0.74 Bn |
| 109 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -7.93 | — | 1.26 Bn |
| 110 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -4.90 | — | 1.26 Bn |
| 111 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -28.78 | 3.20 | 1.15 Bn |
| 112 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.25 Bn | -18.17 | — | 1.25 Bn |
| 113 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.24 Bn | -12.42 | 51.51 | 1.24 Bn |
| 114 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -27.82 | — | 1.00 Bn |
| 115 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -20.55 | — | 1.18 Bn |
| 116 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -9.12 | 41.06 | 0.55 Bn |
| 117 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | -9.77 | — | 1.10 Bn |
| 118 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.06 Bn | -118.02 | — | 1.06 Bn |
| 119 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 6.67 | 5.60 | 0.93 Bn |
| 120 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | -15.63 | 4.14 | 0.71 Bn |
| 121 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | -72.45 | — | 0.95 Bn |
| 122 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -16.83 | 2.09 | 0.66 Bn |
| 123 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -4.90 | 14.37 | 0.57 Bn |
| 124 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | 2.80 | 3.28 | 0.81 Bn |
| 125 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | 20.87 | 8.50 | 0.50 Bn |
| 126 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | -16.32 | 881.20 | 0.88 Bn |
| 127 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.86 Bn | -11.07 | 104.97 | 0.86 Bn |
| 128 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.85 Bn | -4.78 | — | 0.85 Bn |
| 129 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.84 Bn | -8.36 | — | 0.84 Bn |
| 130 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -10.71 | 44.17 | 0.48 Bn |
| 131 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -6.79 | — | 0.79 Bn |
| 132 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -124.74 | 2.37 | 0.63 Bn |
| 133 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | -6.55 | — | 0.71 Bn |
| 134 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.73 Bn | 554.70 | 9.71 | 0.41 Bn |
| 135 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | -3.61 | — | 0.49 Bn |
| 136 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | 3.17 | 1.81 | 0.62 Bn |
| 137 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | -17.73 | 1,120.86 | 0.62 Bn |
| 138 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | -8.59 | — | 0.67 Bn |
| 139 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -362,547.56 | — | 0.64 Bn |
| 140 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | -12.60 | 16.37 | 0.58 Bn |
| 141 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | -10.36 | — | 0.63 Bn |
| 142 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 65.43 | 1.94 | 0.05 Bn |
| 143 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -10.13 | 3.65 | 0.47 Bn |
| 144 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -6.80 | — | 0.59 Bn |
| 145 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -12.04 | — | 0.58 Bn |
| 146 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -3.91 | 557.79 | 0.41 Bn |
| 147 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -4.84 | — | 0.56 Bn |
| 148 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -10.27 | 78.36 | 0.28 Bn |
| 149 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -11.66 | 9.32 | 0.22 Bn |
| 150 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | -15.37 | — | 0.50 Bn |
| 151 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 15.82 | 2.57 | 0.42 Bn |
| 152 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 16.24 | 2.11 | 0.39 Bn |
| 153 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -8.13 | — | 0.47 Bn |
| 154 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -19.83 | — | 0.45 Bn |
| 155 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -3.41 | — | 0.47 Bn |
| 156 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -4.85 | 13.19 | 0.21 Bn |
| 157 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.72 | 15.31 | 0.26 Bn |
| 158 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.68 | 44.52 | 0.24 Bn |
| 159 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -5.85 | — | 0.44 Bn |
| 160 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -4.58 | 42.40 | 0.44 Bn |
| 161 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -7.97 | 19.43 | 0.16 Bn |
| 162 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | -5.45 | — | 0.43 Bn |
| 163 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -6.49 | 6.28 | 0.22 Bn |
| 164 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.27 | — | 0.24 Bn |
| 165 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -1.28 | 139.55 | 0.21 Bn |
| 166 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -4.78 | — | 0.38 Bn |
| 167 | HMDCF | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | — | — | 0.39 Bn |
| 168 | DMAC | DiaMedica Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -11.03 | — | 0.36 Bn |
| 169 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -3.16 | — | 0.36 Bn |
| 170 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | 3.71 | 2.65 | 0.34 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -4.13 | — | 0.34 Bn |
| 172 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -6.68 | — | 0.33 Bn |
| 173 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | -2.93 | 3.70 | 0.17 Bn |
| 174 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | -2.05 | 104.23 | 0.33 Bn |
| 175 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -4.33 | — | 0.31 Bn |
| 176 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -10.84 | — | 0.31 Bn |
| 177 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | -1.58 | 4.90 | 0.30 Bn |
| 178 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 64.31 | — | 0.19 Bn |
| 179 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -5.32 | 13.14 | 0.29 Bn |
| 180 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -5.29 | 7.86 | 0.22 Bn |
| 181 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -17.36 | 1.67 | 0.17 Bn |
| 182 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -3.35 | — | 0.28 Bn |
| 183 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -1.82 | 59.24 | 0.28 Bn |
| 184 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -7.64 | — | 0.27 Bn |
| 185 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -3.12 | 19.81 | 0.10 Bn |
| 186 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -4.35 | 23.24 | 0.27 Bn |
| 187 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -18.88 | — | 0.15 Bn |
| 188 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -13.77 | — | 0.25 Bn |
| 189 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -3.77 | 17.81 | 0.21 Bn |
| 190 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -1.49 | — | 0.25 Bn |
| 191 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 6.88 | 3.31 | 0.16 Bn |
| 192 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -3.15 | 4.34 | 0.08 Bn |
| 193 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -10.43 | — | 0.23 Bn |
| 194 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -2.20 | — | 0.23 Bn |
| 195 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -5.11 | 54.32 | 0.23 Bn |
| 196 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -1.16 | — | 0.23 Bn |
| 197 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.49 | 6.84 | -0.03 Bn |
| 198 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.66 | 4.31 | 0.11 Bn |
| 199 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -4.44 | 10.20 | 0.08 Bn |
| 200 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.46 | — | 0.19 Bn |
| 201 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.99 | — | 0.22 Bn |
| 202 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 10.05 | 2.66 | 0.17 Bn |
| 203 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -7.27 | — | 0.21 Bn |
| 204 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -13.14 | 32.66 | 0.21 Bn |
| 205 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 1.21 | — | 0.21 Bn |
| 206 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -2.47 | — | 0.20 Bn |
| 207 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -1.16 | 60.09 | 0.19 Bn |
| 208 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -2.55 | — | 0.34 Bn |
| 209 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -116.03 | — | 0.19 Bn |
| 210 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.61 | 75.57 | 0.06 Bn |
| 211 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.51 | 214.11 | 0.18 Bn |
| 212 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -5.57 | 2.72 | 0.04 Bn |
| 213 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -1.42 | 2.28 | -0.05 Bn |
| 214 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -4.87 | 14.38 | 0.14 Bn |
| 215 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -4.96 | 33.39 | 0.17 Bn |
| 216 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 | 2,035.87 | -0.02 Bn |
| 217 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -2.91 | — | 0.16 Bn |
| 218 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -6.25 | 43.96 | 0.12 Bn |
| 219 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | — | — | -0.02 Bn |
| 220 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -10.49 | — | 0.14 Bn |
| 221 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.87 | — | -0.03 Bn |
| 222 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -5.06 | — | 0.14 Bn |
| 223 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -1.72 | 6.38 | 0.13 Bn |
| 224 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.56 | — | 0.14 Bn |
| 225 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | — | — | -0.02 Bn |
| 226 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -4.13 | 1,363.19 | 0.14 Bn |
| 227 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -4.47 | — | 0.14 Bn |
| 228 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -5.01 | 136.38 | 0.14 Bn |
| 229 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -6.55 | — | 0.12 Bn |
| 230 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -2.55 | — | 0.01 Bn |
| 231 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -1.50 | — | 0.12 Bn |
| 232 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -1.68 | 39.24 | 0.12 Bn |
| 233 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -2.72 | — | 0.06 Bn |
| 234 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -5.00 | 13.92 | 0.07 Bn |
| 235 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.18 | — | 0.11 Bn |
| 236 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -3.32 | — | 0.10 Bn |
| 237 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -9.67 | — | 0.09 Bn |
| 238 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 2.80 | — | 0.09 Bn |
| 239 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.94 | — | 0.09 Bn |
| 240 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.50 | — | 0.08 Bn |
| 241 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.21 | — | 0.09 Bn |
| 242 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.01 | 60.89 | 0.09 Bn |
| 243 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 244 | TLPH | Talphera, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -6.42 | 90,632.28 | 0.09 Bn |
| 245 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 10.35 | 1.32 | -0.06 Bn |
| 246 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 2.12 | 139.00 | 0.09 Bn |
| 247 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -3.87 | — | 0.09 Bn |
| 248 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -118.64 | — | 0.09 Bn |
| 249 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 | — | 0.08 Bn |
| 250 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.48 | — | 0.08 Bn |
| 251 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -2.97 | — | 0.05 Bn |
| 252 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -5.29 | — | 0.07 Bn |
| 253 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -4.20 | — | 0.08 Bn |
| 254 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -2.17 | — | 0.08 Bn |
| 255 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.79 | 126.99 | 0.07 Bn |
| 256 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 12.11 | 1.50 | 0.02 Bn |
| 257 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.62 | — | 0.07 Bn |
| 258 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.92 | 17.32 | 0.03 Bn |
| 259 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -7.26 | 0.43 | 0.02 Bn |
| 260 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -7.96 | — | 0.06 Bn |
| 261 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.20 | — | 0.06 Bn |
| 262 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -3.04 | 1,632.72 | 0.06 Bn |
| 263 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.67 | 29.85 | 0.06 Bn |
| 264 | BDRX | Biodexa Pharmaceuticals Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -6.38 | — | 0.04 Bn |
| 265 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.19 | — | 0.03 Bn |
| 266 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -3.48 | 2.74 | -0.06 Bn |
| 267 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.43 | 5.09 | 0.05 Bn |
| 268 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.27 | — | 0.05 Bn |
| 269 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.93 | 3.86 | 0.05 Bn |
| 270 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.77 | 294.15 | -0.01 Bn |
| 271 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.39 | 2.24 | 0.05 Bn |
| 272 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -4.34 | — | 0.05 Bn |
| 273 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.57 | 342.82 | 0.02 Bn |
| 274 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.95 | — | 0.04 Bn |
| 275 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.09 Bn |
| 276 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.72 | 4.79 | 0.04 Bn |
| 277 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.71 | — | 0.03 Bn |
| 278 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.04 | 79.85 | 0.04 Bn |
| 279 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.66 | — | 0.04 Bn |
| 280 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -6.19 | 0.38 | 0.03 Bn |
| 281 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.18 | 4.58 | 0.06 Bn |
| 282 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.12 | 0.94 | 0.02 Bn |
| 283 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -21.82 | — | 0.04 Bn |
| 284 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 285 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.53 | — | 0.03 Bn |
| 286 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 2.86 | 0.92 | 0.03 Bn |
| 287 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 288 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -12.26 | 93.50 | 0.03 Bn |
| 289 | YDESW | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | — | — | 0.03 Bn |
| 290 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.31 | 37.53 | 0.03 Bn |
| 291 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.24 | — | 0.03 Bn |
| 292 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -23.02 | — | 0.03 Bn |
| 293 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.30 | 869.19 | 0.02 Bn |
| 294 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -3.54 | — | 0.03 Bn |
| 295 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.55 | — | 0.02 Bn |
| 296 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.93 | — | 0.02 Bn |
| 297 | RDPTF | Radiopharm Theranostics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.28 | 97.58 | 0.02 Bn |
| 298 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.14 | 261.63 | 0.03 Bn |
| 299 | CNSY | Cerenome, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.73 | 4.80 | 0.01 Bn |
| 300 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.31 | 2.67 | 0.01 Bn |